Skip to main content
Top
Published in: Clinical Rheumatology 3/2007

01-03-2007 | Review

The association of −627 interleukin-10 promoter polymorphism in Chinese patients with systemic lupus erythematosus

Authors: Po-Wen Lin, Chung-Ming Huang, Chiu-Ching Huang, Chang-Hai Tsai, Jeffrey J. P. Tsai, Chin-Ping Chang, Fuu-Jen Tsai

Published in: Clinical Rheumatology | Issue 3/2007

Login to get access

Abstract

The objective of the study is to examine whether interleukin-10 (IL-10) promoter polymorphism is a marker of susceptibility of systemic lupus erythematosus (SLE) in Chinese patients in Taiwan. The study included 119 Chinese patients with SLE. One hundred unrelated healthy individuals living in central Taiwan served as control subjects. Each polymorphism was detected as a result of a polymerase chain reaction (PCR)-based restriction analysis. The PCR product length was determined to be 412 bp (CC) whereas two fragments of 236 and 176 bp were determined to be excisable lengths (AA). The relationship between the IL-10 gene polymorphism and clinical manifestations of SLE was evaluated. For the genotype and allelic frequency, there were statistically significant differences between the SLE patients and the normal control subjects (p=0.007 and 0.003, respectively). But we did not detect any association of carriage rate of the IL-10 polymorphism and the normal control subjects (p=0.077). Furthermore, we did not detect any association of IL-10 genotype with antinuclear antibody, malar rash, photosensitivity, discoid lupus, mucosal ulcer, arthritis, serositis, hematology, immunology, involvement of central nervous system, and renal disease involvement in the SLE patients. The significant relation of −627 IL-10 genotype and allelic frequency with SLE implies that the IL-10 gene polymorphism can serve as a candidate gene marker for further study in patients with SLE in Taiwan.
Literature
1.
go back to reference Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P et al (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839PubMedCrossRef Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P et al (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839PubMedCrossRef
2.
go back to reference Mongan AE, Ramdahin S, Warrington RJ (1999) Interleukin-10 response abnormalities in systemic lupus erythematosus. Scand J Immunol 46:406CrossRef Mongan AE, Ramdahin S, Warrington RJ (1999) Interleukin-10 response abnormalities in systemic lupus erythematosus. Scand J Immunol 46:406CrossRef
3.
go back to reference Lacki JK, Samborski W, Mackiewicz SH (1997) Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 16:275PubMedCrossRef Lacki JK, Samborski W, Mackiewicz SH (1997) Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 16:275PubMedCrossRef
4.
go back to reference Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, Galanaud P, Emilie D (1994) In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren’s syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 37:1647PubMed Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, Galanaud P, Emilie D (1994) In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren’s syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 37:1647PubMed
5.
go back to reference Howard M, O’Garra A, Ishida H, de Waal Malefyt R, de Vries J (1992) Biological properties of interleukin 10. J Clin Immunol 12:239–247PubMedCrossRef Howard M, O’Garra A, Ishida H, de Waal Malefyt R, de Vries J (1992) Biological properties of interleukin 10. J Clin Immunol 12:239–247PubMedCrossRef
6.
go back to reference Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA (1995) A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154:5492–5499PubMed Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA (1995) A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154:5492–5499PubMed
7.
go back to reference Te Velde AA, de Waal Malefijt R, Huijbens RJ, de Vries JE, Figdor CG (1992) IL-10 stimulates monocyte FcγR surface expression and cytotoxic activity: distinct regulation of antibody-dependent cellular cytotoxicity by IFN-γ, IL-4, and IL-10. J Immunol 149:4048 Te Velde AA, de Waal Malefijt R, Huijbens RJ, de Vries JE, Figdor CG (1992) IL-10 stimulates monocyte FcγR surface expression and cytotoxic activity: distinct regulation of antibody-dependent cellular cytotoxicity by IFN-γ, IL-4, and IL-10. J Immunol 149:4048
8.
go back to reference Lalani I, Bhol K, Ahmed AR (1997) Interleukin-10: biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol 79:469PubMedCrossRef Lalani I, Bhol K, Ahmed AR (1997) Interleukin-10: biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol 79:469PubMedCrossRef
9.
go back to reference Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P et al (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839PubMedCrossRef Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P et al (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839PubMedCrossRef
10.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271PubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271PubMed
11.
go back to reference Eskdale J, Kube D, Tesch H, Gallagher G (1997) Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 46(2):120–128PubMedCrossRef Eskdale J, Kube D, Tesch H, Gallagher G (1997) Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 46(2):120–128PubMedCrossRef
12.
go back to reference Bienvenu J, Doche C, Gutowski MC, Lenoble M, Lepape A, Perdrix JP (1995) Production of pro-inflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 25(Suppl 2):80–84CrossRef Bienvenu J, Doche C, Gutowski MC, Lenoble M, Lepape A, Perdrix JP (1995) Production of pro-inflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 25(Suppl 2):80–84CrossRef
13.
go back to reference Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24(1):1–8 (Feb)PubMed Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24(1):1–8 (Feb)PubMed
14.
go back to reference Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE, Hutchinson IV (1997) Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 24:2314–2317PubMed Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE, Hutchinson IV (1997) Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 24:2314–2317PubMed
15.
go back to reference Mok CC, Lanchbury JS, Chan DW, Lau CS (1998) Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 41:1090–1095PubMedCrossRef Mok CC, Lanchbury JS, Chan DW, Lau CS (1998) Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 41:1090–1095PubMedCrossRef
16.
go back to reference Gibson AW, Edberg JC, Wu J, Westendom RG, Huizinga TW, Kimberly RP (2001) Novel single nucleotide polymorphism in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166:3915–3922PubMed Gibson AW, Edberg JC, Wu J, Westendom RG, Huizinga TW, Kimberly RP (2001) Novel single nucleotide polymorphism in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166:3915–3922PubMed
17.
go back to reference Lim S, Crawley E, Woo P, Barnes PJ (1998) Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 352(9122):113 (Jul 11)PubMedCrossRef Lim S, Crawley E, Woo P, Barnes PJ (1998) Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 352(9122):113 (Jul 11)PubMedCrossRef
18.
go back to reference Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S (1996) Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 97(6):1288–1296 (Jun)PubMedCrossRef Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S (1996) Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 97(6):1288–1296 (Jun)PubMedCrossRef
19.
go back to reference Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP (2000) Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 46(4):540–545 (Apr)PubMedCrossRef Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP (2000) Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 46(4):540–545 (Apr)PubMedCrossRef
20.
go back to reference Guseva IA, Omarbekova Zh, Myakotkin VA (2003) Polymorphism of FcgRIIIA-158F/V and promotion region of IL-10 genes in systemic lupus erythematosus in Kazakhs. Therapeutic Archives 5:36 Guseva IA, Omarbekova Zh, Myakotkin VA (2003) Polymorphism of FcgRIIIA-158F/V and promotion region of IL-10 genes in systemic lupus erythematosus in Kazakhs. Therapeutic Archives 5:36
21.
go back to reference Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW (1998) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 5:9465CrossRef Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW (1998) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 5:9465CrossRef
22.
go back to reference Mehrian R Jr, Quismorio FP, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, Gauderman WJ, Morrison J, Brautbar C, Jacob CO (1998) Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 41:596PubMedCrossRef Mehrian R Jr, Quismorio FP, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, Gauderman WJ, Morrison J, Brautbar C, Jacob CO (1998) Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 41:596PubMedCrossRef
23.
go back to reference Eskdale J, McNicholl J, Wordsworth P, Jonas B, Huizinga T, Field M, Gallagher G (1998) Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet 352:1282PubMedCrossRef Eskdale J, McNicholl J, Wordsworth P, Jonas B, Huizinga T, Field M, Gallagher G (1998) Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet 352:1282PubMedCrossRef
24.
go back to reference Keijsers V, Verweij CL, Westendorp RGJ, Breedveld FC, Huizinga TWJ (1997) IL-10 polymorphisms in relation to production and rheumatoid arthritis. Arthritis Rheum 40(Suppl 9):S179 Keijsers V, Verweij CL, Westendorp RGJ, Breedveld FC, Huizinga TWJ (1997) IL-10 polymorphisms in relation to production and rheumatoid arthritis. Arthritis Rheum 40(Suppl 9):S179
25.
go back to reference Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE, Hutchinson IV (1997) Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 24:2314PubMed Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE, Hutchinson IV (1997) Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 24:2314PubMed
26.
go back to reference Mok CC, Lanchbury JS, Chan DW, Lau CS (1998) Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 41:1090PubMedCrossRef Mok CC, Lanchbury JS, Chan DW, Lau CS (1998) Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 41:1090PubMedCrossRef
27.
go back to reference Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G (1997) Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 49:635PubMedCrossRef Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G (1997) Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 49:635PubMedCrossRef
28.
go back to reference Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P (1999) Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42:1101PubMedCrossRef Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P (1999) Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42:1101PubMedCrossRef
29.
go back to reference D’Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P (2000) Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 43:120PubMedCrossRef D’Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P (2000) Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 43:120PubMedCrossRef
30.
go back to reference Pratt RE, Dzau VJ (1999) Genomics and hypertension concepts, potentials, and opportunities. Hypertension 33:238–247PubMed Pratt RE, Dzau VJ (1999) Genomics and hypertension concepts, potentials, and opportunities. Hypertension 33:238–247PubMed
Metadata
Title
The association of −627 interleukin-10 promoter polymorphism in Chinese patients with systemic lupus erythematosus
Authors
Po-Wen Lin
Chung-Ming Huang
Chiu-Ching Huang
Chang-Hai Tsai
Jeffrey J. P. Tsai
Chin-Ping Chang
Fuu-Jen Tsai
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0329-8

Other articles of this Issue 3/2007

Clinical Rheumatology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.